VYNE Therapeutics (VYNE) Accumulated Expenses (2016 - 2026)

VYNE Therapeutics' Accumulated Expenses history runs 11 years deep, the most recent figure standing at $86000.0 for Q1 2026.

• Quarterly Accumulated Expenses fell 98.75% year-over-year to $86000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86000.0 (down 98.75% YoY) and the FY2025 annual result came in at $941000.0, down 34.1% from the prior year.
• Accumulated Expenses was $86000.0 for Q1 2026 at VYNE Therapeutics, down from $941000.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.9 million in Q1 2025 and bottomed at $86000.0 in Q1 2026.
• A 5-year average of $2.7 million and a median of $2.3 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 506.34% — and 2026, when it tumbled 98.75%.
• VYNE Therapeutics' Accumulated Expenses stood at $2.4 million in 2022, then surged by 73.65% to $4.1 million in 2023, then plunged by 65.33% to $1.4 million in 2024, then slumped by 34.1% to $941000.0 in 2025, then sank by 90.86% to $86000.0 in 2026.
• Business Quant data shows VYNE's Accumulated Expenses at $86000.0 in Q1 2026, $941000.0 in Q4 2025, and $3.6 million in Q2 2025.